The InDx CMC Implant. A new treatment for thumb base joint arthritis.broad
InDx CMC Implant · Horizon Europe grant · 2022-11-01–2024-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
The InDx CMC Implant is for the treatment of thumb base joint arthritis. It is the first evidence-based, surgeon-led innovation, implant solution for this major clinical problem. The potential market is estimated at over €700M per year.The implant meets a major unmet clinical need for an ageing EU population. The implant re-creates the natural joint biomechanics to give a more reliable and clinically superior outcome for patients. This disruptive technology can change the treatment landscape for this condition. The implant provides an exciting new treatment option for an under-served population. It has been shown to eliminate pain and restore full joint mobility. The InDx Implant is smarter, safer, and simpler to insert than any current treatment options.The InDx Implant is patented, with a clear pathway to regulatory clearance in the EU and US. The company is led by a physician-innovator and is supported by medical device industry veterans and world-leading hand surgeons.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| LOCI ORTHOPAEDICS LIMITED | IE | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.